Interference with Cripto mRNA levels directly by siRNA, or via the inhibition of c-Src with Saracatinib, or ALK4 kinase activity via a small molecule inhibitor, abrogated the tumor-promoting effects of Cripto [88]. The gene discussed is SRC; the disease is neoplasm.